Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITIGATE phase 3 trial of inebilizumab for IgG4-related disease
MOH_2021-02-14_009752Phase 3Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Inebilizumab with Placebo (2 arms). Started Jan 2021; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on MOH_2021-02-14_009752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-14_009752.